Paper Details

  1. Home
  2. Paper Details

ABVD or BEACOPP<sub>baseline</sub> along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d'&#201;tude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial.

Author: , AnglaretBruno, AudhuyBruno, BolognaSerge, BouabdallahRéda, BricePauline, BrièreJosette, CardePatrice, CasasnovasOlivier, DelarueRichard, EghbaliHouchingue, FerméChristophe, Henry-AmarMichel, JanvierMaud, LugtenburgPieternella J, LybeertMarnix L M, MarjanovicZora, NoordijkEvert M, RaemaekersJohn M M, RemanOumédaly, SallesGilles, SebbanCatherine, SpinaMichele, TersteegRobbert J H A, ThomasJosé, ThyssAntoine, VranovskyAndrej, de JongDaphne, de WeerdtOkke, van ImhoffGustaaf W

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Four cycles of ABVD followed by involved-field radiotherapy yielded high disease control in patients with early-stage Hodgkin lymphoma (HL) and risk factors.
Paper Details　
Original Abstract of the Article :
PURPOSE: For early-stage Hodgkin lymphoma (HL), optimal chemotherapy regimen and the number of cycles to be delivered remain to settle down. The H9-U trial compared three modalities of chemotherapy followed by involved-field radiotherapy (IFRT) in patients with stage I-II HL and risk factors (NCT000...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ejca.2017.05.005

データ提供：米国国立医学図書館（NLM）

Navigating the Complexities of Early-Stage Hodgkin Lymphoma Treatment

The fight against cancer is a constant struggle, with researchers seeking new and effective treatments to improve patient outcomes. This study explores the optimal treatment approach for early-stage Hodgkin lymphoma (HL) patients with risk factors. The researchers conducted a large, multicenter, randomized trial to compare the efficacy of three different chemotherapy regimens followed by involved-field radiotherapy (IFRT): 6-ABVD-IFRT, 4-ABVD-IFRT, and 4-BEACOPP-IFRT.

The study found that all three treatment regimens achieved high rates of disease control, with no significant differences in 5-year event-free survival. The researchers concluded that 4-ABVD-IFRT is an effective and well-tolerated treatment option for early-stage HL patients with risk factors, offering comparable efficacy to 6-ABVD-IFRT and 4-BEACOPP-IFRT. The study also highlighted the importance of individualizing treatment decisions based on patient characteristics and risk factors.

Optimal Treatment for Early-Stage Hodgkin Lymphoma: 4-ABVD-IFRT Shows Promise

The study's findings provide valuable insights into the treatment of early-stage HL patients with risk factors. The researchers suggest that 4-ABVD-IFRT is a viable and effective treatment option, offering a balance of efficacy and tolerability. The study also emphasizes the importance of carefully considering individual patient characteristics and risk factors when making treatment decisions.

Health Implications and Lifestyle Considerations

The study underscores the importance of seeking professional medical advice for the diagnosis and treatment of Hodgkin lymphoma. The researchers recommend that patients with HL discuss their individual circumstances and preferences with their healthcare provider to determine the most appropriate treatment approach. The study also highlights the importance of ongoing research to develop new and improved treatments for HL, improving outcomes and reducing side effects.

Dr.Camel's Conclusion

The fight against Hodgkin lymphoma is a challenging journey, much like a caravan traversing a vast desert. This study sheds light on the efficacy of different treatment approaches, providing valuable insights for physicians and patients alike. The quest for better treatments for HL continues, fueled by the pursuit of personalized medicine and the unwavering commitment to improving patient outcomes.

Date :
  1. Date Completed 2017-08-25
  2. Date Revised 2018-01-21
Further Info :

Pubmed ID

28601705

DOI: Digital Object Identifier

10.1016/j.ejca.2017.05.005

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.